Group 1 - Sanofi's innovative drug company, Sangfor, has granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707, marking a significant milestone for domestic pharmaceutical companies in entering the global market [1] - Pfizer will pay a non-refundable and non-offsettable upfront payment of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales revenue share based on product sales in authorized regions [1] Group 2 - Yipinhong announced the acquisition of a 15.25% stake in its subsidiary Guangzhou Rui'an Bo from minority shareholder Arthrosi for $6.8 million (approximately 49 million RMB) to enhance its market rights for the innovative drug AR882 in China and to promote efficient research and rapid market entry [2] - The transaction's pricing and the ongoing technical support from Arthrosi will be closely monitored for future clinical progress and market access efficiency [2] Group 3 - Huasheng Technology received an administrative regulatory measure from the Sichuan Securities Regulatory Bureau, which ordered the company to rectify issues related to accounting irregularities, non-operating fund occupation, and inadequate internal controls [3] - The regulatory action highlights weaknesses in the company's governance structure and compliance awareness, potentially affecting the rights of minority investors [3] Group 4 - Fosun Pharma announced the resignation of Rong Yang, CEO of its U.S. subsidiary, due to personal reasons, raising concerns about the continuity of leadership and strategic direction in the critical U.S. market for innovative drug commercialization [4] - The company is currently expanding its capabilities in the U.S. for both generic and innovative drug registration and commercialization [4]

Core Viewpoint - The collaboration between Sanofi and Pfizer for the dual-specific antibody SSGJ-707 marks a significant step in the global commercialization of innovative cancer therapies, enhancing the international recognition and accessibility of Sanofi's products [1][2]. Company Summary - Sanofi and its affiliates granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the dual-specific antibody SSGJ-707, with Pfizer retaining rights for commercialization in mainland China through additional payments [1]. - Pfizer will pay an upfront non-refundable fee of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales share based on product sales in authorized regions [1]. - The antibody SSGJ-707 targets PD-1 and VEGF, having received breakthrough therapy designation from the National Medical Products Administration for treating advanced non-small cell lung cancer (NSCLC) [1][2]. Industry Summary - The collaboration signifies recognition of Sanofi's dual-specific antibody research platform by a leading international company, which is expected to enhance the global reach and acceptance of its products [2]. - The SSGJ-707 is currently in Phase III clinical trials for NSCLC and Phase II for other indications, indicating a robust pipeline for Sanofi's innovative therapies [2]. - The trend of Chinese innovative drug companies entering into licensing agreements with multinational pharmaceutical companies is growing, driven by the increasing recognition of Chinese innovation and the need for multinational firms to address patent cliffs [3][4].

证券代码： 688336 证券简称：三生国健 公告编号：2025-023 三生国健药业（上海）股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据上海证券交易所相关规定，公司对相关问题进行了自查，并 发函向公司控股股东及实际控制人核实。现将有关情况： 说明如下： 处的行业政策未发生重大调整。 ? 三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）股票交易连续两个交易日内（2025 年 5 月 19 日、2025 年 易所交易规则》 《上海证券交易所科创板股票异常交易实时监控细则》 的有关规定，属于股票交易异常波动情形。 ? 经公司自查并向控股股东及实际控制人核实，截止本公告披露 日，除公司已披露信息外，公司及公司控股股东、实际控制人不存在 筹划关于公司的应披露而未披露的重大事项的情况，公司日常经营情 况正常，未发生重大变化，所处的行业政策未发生重大调整。 ? 公司及本公司的关联方三生制药和沈阳三生制药有限责任公 司（以下简称"沈阳三生"，以下合称"许可方 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-022 三生国健药业（上海）股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络 投票相结合的方式 召开地点：中国（上海）自由贸易试验区李冰路 399 号公司会议 室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 5 日 至2025 年 6 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段， 即 9:15-9:25,9:30-11:30， 的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票 程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通 投资者的投票，应按照《上海证券交易所科创板上市公司自律监管指 引第 ...

证券代码： 688336 证券简称：三生国健 公告编号：2025-023 三生国健药业（上海）股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）股票交易连续两个交易日内（2025 年 5 月 19 日、2025 年 5 月 20 日）日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交 易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》 的有关规定，属于股票交易异常波动情形。 经公司自查并向控股股东及实际控制人核实，截止本公告披露 日，除公司已披露信息外，公司及公司控股股东、实际控制人不存在 筹划关于公司的应披露而未披露的重大事项的情况，公司日常经营情 况正常，未发生重大变化，所处的行业政策未发生重大调整。 公司及本公司的关联方三生制药和沈阳三生制药有限责任公 司（以下简称"沈阳三生"，以下合称"许可方"）共同授予被许可 方辉瑞公司（Pfizer Inc.）（以下简称"被许可方"）在许可区域 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-022 三生国健药业（上海）股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络 投票相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 5 日 10 点 00 分 召开地点：中国（上海）自由贸易试验区李冰路 399 号公司会议 室 股东大会召开日期：2025年6月5日 本次股东大会采用的网络投票系统：上海证券交易所股东大 会网络投票系统 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 （七） 涉及公开征集股东投票权 不涉及。 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | | | 投票股东类型 | | --- | --- ...

Market Overview - A-shares experienced a broad rally on May 20, with the Shanghai Composite Index closing up 0.38% at 3380.48 points, the Shenzhen Component up 0.77% at 10249.17 points, and the ChiNext Index up 0.77% at 2048.46 points. The total trading volume across the three exchanges reached 121.14 billion yuan, an increase of 9.23 billion yuan from the previous day [1][2]. Pet Economy - The pet economy concept saw significant gains, with Tianyuan Pet (301335) hitting a 20% limit up and reaching a new high. Lusi Co. (832419) also hit a limit up, marking a new high. Other companies in this sector, such as Bei Yin Mei (002570) and Yi Yi Co. (001206), also experienced limit up [4][5][6]. - Analysts noted that the pet market has maintained high growth rates in recent years, benefiting from domestic brand replacement effects and improvements in product and brand strength. This has led to significant year-on-year sales growth and price increases for domestic brands [7]. Innovative Drug Sector - The innovative drug sector showed strong performance, with Yipin Hong (300723) and San Sheng Guo Jian (688336) both hitting the 20% limit up. Other companies like Rongchang Bio (688331) and Yifang Bio (688382) saw increases of approximately 16% [8][9]. - San Sheng Guo Jian announced a collaboration with Pfizer for the exclusive global development and commercialization rights of a dual-target antibody, SSGJ-707, which has shown promising results in clinical trials for non-small cell lung cancer [10][11]. Shipping Sector - The shipping sector experienced a significant pullback, with companies like Guo Hang Yuan Yang (833171) dropping nearly 18%, and others such as Fenghuang Shipping (000520) and Lianyungang (601008) hitting their daily limit down [16][17]. - Lianyungang, which had seen five consecutive limit up days, reported a 48.01% year-on-year decline in net profit for the first quarter of 2025, raising concerns among investors [18][19].

5月20日，A股主要指数震荡上行，沪指收涨0.38%报3380点，深证成指涨0.77%，创业板指涨0.77%，北证50指数涨1.22%创历史新高。 全天成交1.21万亿元，较前一交易日增量923亿元，全市场超3800股上涨。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 上证指数 | Friend | 3380.48 | +12.90 | 40.38% | | 000001 | Now | | | | | 创业板指 | | 2048.46 | +15.70 | +0.77% | | 399006 | | | | | | 深证成指 | | 10249.17 | +78.08 +0.77% | | | 100002 | AF | | | | 盘面上，新消费方向走强，宠物经济板块持续爆发，盲盒经济、谷子经济板块走高，培育钻石板块拉升，家用轻工板块走强，美容护理、人造肉 及珠宝首饰等板块涨幅居前。另外，航运港口板块下挫，PEEK材料板块走低，航天航空、碳纤维、可控核聚变及钛白粉等板块跌幅居前。 | 行业热力图 v 领涨板块 | | | | | ...

Market Performance - The three major A-share indices all rose, with the Shanghai Composite Index up 0.38%, the Shenzhen Component Index up 0.77%, and the ChiNext Index also up 0.77 [1][2] Consumer Sector - The consumer sector showed strong performance today, particularly in areas such as the pet economy, cultivated diamonds, beauty care, and millet economy, which had the highest gains [1][2] - Analysts noted that consumer demand is diversifying, with emotional, health, and beauty consumption needs continuing to evolve, leading to ongoing opportunities in single product categories like pet products and snacks [2] Beauty Care Sector - According to Zhonghang Securities, the beauty care sector is expected to see structural opportunities due to favorable policies, restored consumer confidence, and technological innovations [2] - The upcoming "618" shopping festival and optimized brand promotion strategies are seen as short-term catalysts for the beauty care sector [2] Pet Economy Sector - CITIC Securities forecasts that the pet economy sector will continue to grow through 2025, highlighting its resilience and the potential for increased market concentration as the industry matures [2] - The domestic market is currently characterized by "large industry, small leaders," suggesting that leading companies can enhance market share through product innovation, branding, and channel development [2] Pharmaceutical Sector - Pharmaceutical stocks surged today, with Sanofi's stock hitting the daily limit, marking two consecutive trading days of gains [3] - Sanofi announced a collaboration with Pfizer, granting exclusive rights for the development, production, and commercialization of a product, with an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [3] Market Highlights - CATL's listing on the Hong Kong stock market saw significant gains, while its A-share rose by 1.15% [3] - Some high-profile stocks experienced volatility, with companies like Lijun Co., Youfu Co., and Ningbo Ocean facing significant declines [3]

东海证券指出，我国创新药具备研发成本低、效率高的优点，或成为BD交易首选，中国有望成为低成本研发与生产中心，加速从"仿制跟随"向"创新主 导"转型。大型跨国药企在更严格的定价体系下可能积极寻求降低研发生产成本的路径，我国CXO产业链或将进一步巩固市场地位。仿制药方面，美国仿制 药市场因价格压缩可能引发生产商退出，导致供应短缺，我国具备ANDA批件积累的仿制药企业有望抢占市场份额。建议关注创新药链、器械设备、中药、 医疗服务、连锁药店等细分板块及个股的投资机会。 科创综指ETF华夏紧密跟踪上证科创板综合指数，上证科创板综合指数由上海证券交易所符合条件的科创板上市公司证券组成指数样本，并将样本分红计入 指数收益，反映上海证券交易所科创板上市公司证券在计入分红收益后的整体表现。 科创综指ETF华夏(589000)，场外联接(华夏上证科创板综合ETF联接A：023719；华夏上证科创板综合ETF联接C：023720)。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 截至2025年5月20日 14:24，上证科创板综合指数(000680)上涨0.57%，成分股三生国健(688336)上涨19. ...